FDA Clearance Tracker · P990056-S039
Elecsys total PSA, total PSA CalSet II
Last checked: Nov 20, 2026Latest source record: Mar 23, 2023 (this decision)Source: openFDAMethods & limitations
Decided
Mar 23, 2023
Approved
Time to decision
177 days
Received Sep 27, 2022. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P990056-S039
- Device name
- Elecsys total PSA, total PSA CalSet II
- Applicant
- Roche Diagnostics Corp.
- Applicant location
- Indianapolis, IN
- Received
- Sep 27, 2022
- Decided
- Mar 23, 2023
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P990056
Device type
- Device type
- Total, prostate specific antigen (noncomplexed & complexed) for detection of prostate cancer (MTF)
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval to extend application of the Elecsys total PSA immunoassay onto the cobas e 402 immunoassay analyzer
Source documents
Other decisions for Roche Diagnostics Corp.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
No other decisions since 2015 under this exact applicant name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.